News
Goldman Sachs Gr GS is set to give its latest quarterly earnings report on Monday, 2025-04-14. Here's what investors need to know before the announcement. Analysts estimate that Goldman Sachs Gr ...
Tariffs are expected to put a damper on automotive sales and production. Goldman Sachs lowered their U.S. sales estimate by 850,000 units for 2025. Next year could be even worse as sales could dip ...
Goldman Sachs rescinded their recession base case within a few hours. Right below 1 p.m., its economists wrote that they expected to change their forecast for the U.S. economy to a recession if ...
Goldman Sachs reversed its recession forecast just moments after President Donald Trump announced a 90-day pause on his “Liberation Day” tariffs. The investment giant had raised its recession ...
Trump's 104% tariffs could cut down China’s GDP growth by 2.4 percentage points, warns Goldman Sachs
Goldman Sachs forecasts a lower 4.5% growth for China, against its 5% target. These tariffs, along with levies on other nations like Lesotho, Vietnam, and the EU, escalate global trade tensions.
Goldman Sachs Group Inc. economists said they now see a 65% chance of a US recession in the next 12 months, citing President Donald Trump’s tariffs on US trading partners. “We think the White ...
Goldman Sachs reversed its prediction that the United States will enter a recession following President Donald Trump‘s decision to pause reciprocal tariffs on dozens of countries for 90 days. “ ...
Hosted on MSN18d
Goldman Sachs Downgrades Bristol-Myers Squibb (BMY)Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Buy to Neutral. Analyst Price Forecast Suggests 14.83% Upside As of April 1 ...
Investing.com-- Markets may still be underestimating the risk of a full-blown U.S. recession following the sharp escalation in tariffs on Chinese goods, Goldman Sachs analyst said in a note.
Hosted on MSN18d
Goldman Sachs Downgrades Pfizer (PFE)Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral. Analyst Price Forecast Suggests 39.12% Upside As of April 1, 2025 ...
Diccon Hyatt is an experienced financial and economics reporter who has covered the pandemic-era economy in hundreds of stories over the past two years. He's written hundreds of stories breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results